Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia

Background: Numerous medications have been tested in patients with borderli ne personality disorder (BPD) and/or schizotypal personality disorder (SPD) . Although many of the medications tested have been demonstrated to be usef ul, no clear main treatment for BPD has emerged. Despite the efficacy of so me of the medicines, acceptability and side effects have proven to be barri ers to the use of medication. Therefore, an open-label olanzapine trial uti lizing objective ratings was performed. Methods: Patients suffering from BPD and dysthymia were included in an 8-we ek, open-label study of olanzapine monotherapy. The first 4 weeks of the tr ial allowed for flexible dosing; during the last 4 weeks, olanzapine dose w as held constant. Patients were rated on Hopkins Symptoms Checklist 90 (SCL -90), Brief Psychiatric Rating Scale (BPRS), Global Assessment of Function (GAF), Barratt Impulsivity Scale (BIS 11), and Buss-Durkee Hostility Invent ory (BDHI). Results: Eleven patients completed at least 2 weeks; nine of the patients f inished the entire trial. There was a robust and statistically significant reduction in the five global ratings. Within the global ratings, symptoms o f psychoticism, depression, interpersonal sensitivity, and anger were among the symptoms to be reduced. No movement disorder symptoms were noted for a ny of the patients. Conclusions: In this open-label pilot study, patients treated with olanzapi ne showed statistically significant reduction in self-rated and clinician-r ated scales. Symptoms associated with BPD and dysthymia were among those to be substantially reduced Further studies to explore olanzapine's efficacy versus placebo, as well as comparison to other potential treatments for BPD , are important next steps. Biol Psychiatry 1999;46: 1429-1435 (C) 1999 Soc iety of Biological Psychiatry.